×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LPTX – leap therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LPTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/15
07:16 am
lptx
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer [Yahoo! Finance]
High
Report
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer [Yahoo! Finance]
4/15
07:00 am
lptx
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
High
Report
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
3/27
08:15 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/26
04:35 pm
lptx
Micro Cap Soars Following Preliminary Data Update [Globe and Mail, The (Toronto, Canada)]
High
Report
Micro Cap Soars Following Preliminary Data Update [Globe and Mail, The (Toronto, Canada)]
3/26
01:44 pm
lptx
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer [Yahoo! Finance]
Low
Report
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer [Yahoo! Finance]
3/26
08:00 am
lptx
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study [Yahoo! Finance]
Medium
Report
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study [Yahoo! Finance]
3/26
08:00 am
lptx
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
High
Report
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/26
07:05 am
lptx
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
09:55 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: ONSI DOUGLAS E
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: ONSI DOUGLAS E
4/1
09:54 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Granfield Christine
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Granfield Christine
4/1
09:53 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: LAWLOR AUGUSTINE
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: LAWLOR AUGUSTINE
4/1
09:53 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Baum Jason
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Baum Jason
4/1
09:52 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: O'Mahony John Mark
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: O'Mahony John Mark
4/1
09:51 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Sirard Cynthia
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Sirard Cynthia
4/1
09:51 pm
lptx
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Mirabelli Christopher
High
Report
Form 4 LEAP THERAPEUTICS, INC. For: Mar 28 Filed by: Mirabelli Christopher
3/26
05:01 pm
lptx
Form S-8 LEAP THERAPEUTICS, INC.
High
Report
Form S-8 LEAP THERAPEUTICS, INC.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/3
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
51.9%
1/4 Leap Therapeutics Inc (NASDAQ: LPTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 20.6%
2/26 Leap Therapeutics to Present at Cowen 40th Annual Health Care Conference 15.0%
3/23 Form 3 LEAP THERAPEUTICS, INC. For: Mar 12 Filed by: BeiGene, Ltd. 14.5%
4/20 Form SC 13G LEAP THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC 13.8%
3/18 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 17 12.8%
4/23 Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers 12.2%
1/23 Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting 11.7%
6/12 Form 4 LEAP THERAPEUTICS, INC. For: Jun 11 Filed by: LAWLOR AUGUSTINE 10.3%
3/17 Leap Therapeutics Inc (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock. 8.4%
1/4 Leap Therapeutics Inc (NASDAQ: LPTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 20.6%
2/26 Leap Therapeutics to Present at Cowen 40th Annual Health Care Conference 15.0%
3/23 Form 3 LEAP THERAPEUTICS, INC. For: Mar 12 Filed by: BeiGene, Ltd. 14.5%
4/20 Form SC 13G LEAP THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC 13.8%
3/18 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 17 12.8%
4/23 Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers 12.2%
1/23 Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting 11.7%
6/12 Form 4 LEAP THERAPEUTICS, INC. For: Jun 11 Filed by: LAWLOR AUGUSTINE 10.3%
3/17 Leap Therapeutics Inc (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock. 8.4%
TOP News Decliners
11/14
Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.330 ActVsEst 0.000 - In-Line
-53.6%
8/6 Form 8-K LEAP THERAPEUTICS, INC. For: Aug 06 -23.0%
3/18 Leap Therapeutics Announces Executive Leadership Changes -19.3%
9/17 Form 8-K LEAP THERAPEUTICS, INC. For: Sep 16 -18.3%
3/16 Form 10-K LEAP THERAPEUTICS, INC. For: Dec 31 -12.2%
7/11 Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital -7.9%
2/1 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%
3/4 Form 4 LEAP THERAPEUTICS, INC. For: Mar 02 Filed by: LITTLECHILD JOHN W -7.1%
3/9 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 05 -6.4%
6/5 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
8/6 Form 8-K LEAP THERAPEUTICS, INC. For: Aug 06 -23.0%
3/18 Leap Therapeutics Announces Executive Leadership Changes -19.3%
9/17 Form 8-K LEAP THERAPEUTICS, INC. For: Sep 16 -18.3%
3/16 Form 10-K LEAP THERAPEUTICS, INC. For: Dec 31 -12.2%
7/11 Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital -7.9%
2/1 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.6%
3/4 Form 4 LEAP THERAPEUTICS, INC. For: Mar 02 Filed by: LITTLECHILD JOHN W -7.1%
3/9 Form 8-K LEAP THERAPEUTICS, INC. For: Mar 05 -6.4%
6/5 Leap Therapeutics Inc (NASDAQ: LPTX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: